Assessing aneuploidy with repetitive element sequencing.
Christopher DouvilleJoshua David CohenJanine PtakMaria PopoliJoy SchaeferNatalie SillimanLisa DobbynRobert E SchoenJeanne TiePeter GibbsMichael GogginsChristopher L WolfgangTian-Li WangIe-Ming ShihRachel KarchinAnne Marie LennonRalph H HrubanCristian TomasettiChetan BettegowdaKenneth W KinzlerNickolas PapadopoulosBert VogelsteinPublished in: Proceedings of the National Academy of Sciences of the United States of America (2020)
We report a sensitive PCR-based assay called Repetitive Element AneupLoidy Sequencing System (RealSeqS) that can detect aneuploidy in samples containing as little as 3 pg of DNA. Using a single primer pair, we amplified ∼350,000 amplicons distributed throughout the genome. Aneuploidy was detected in 49% of liquid biopsies from a total of 883 nonmetastatic, clinically detected cancers of the colorectum, esophagus, liver, lung, ovary, pancreas, breast, or stomach. Combining aneuploidy with somatic mutation detection and eight standard protein biomarkers yielded a median sensitivity of 80% in these eight cancer types, while only 1% of 812 healthy controls scored positive.